Jack Brzezinski
Associate Professor
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Jack Brzezinski is an Associate Professor at the University of Washington, USA. His research primarily focuses on cancer predisposition syndromes, particularly in pediatric populations, and includes recent work on retinoblastoma, PTEN hamartoma tumor syndrome, and Wilms tumor predisposition. He contributes significant insights into surveillance recommendations and treatment strategies for various tumor syndromes in children.
Articles (10)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Introduction The purpose of this study is to examine the outcomes in children with anaplastic bilateral Wilms tumor (BWT) from study AREN0534 in order to define potential prognostic factors and areas to target in future clinical trials. Methods Demographic and clinical data from AREN0534 study patients with anaplasia (focal anaplasia [FA], or diffuse anaplasia [DA]) were compared. Event‐free survival (EFS) and overall survival (OS) were reported using Kaplan–Meier estimation with 95% confidence bands, and differences in outcomes between FA and DA compared using log‐rank tests. The impact of margin status was analyzed. Results Twenty‐seven children who enrolled on AREN0534 had evidence of anaplasia (17 DA, 10 FA) in at least one kidney and were included in this analysis. Twenty‐six (96%) had BWT. Nineteen percent had anaplastic histology in both kidneys (four of 17 DA, and one of 10 FA). Forty‐six percent with BWT had bilateral nephron‐sparing surgery (NSS); one child who went off protocol therapy, eventually required bilateral completion nephrectomies. Median follow‐up for EFS and OS was 8.6 and 8.7 years from enrollment. Four‐ and 8‐year EFS was 53% [95% confidence interval (CI): 34%–83%] for DA; 4‐year EFS was 80% [95% CI: 59%–100%], and 8‐year EFS 70% [95% CI: 47%–100%] for FA. Three out of 10 children with FA and eight out of 17 children with DA had events. EFS did not differ statistically by margin status ( p = .79; HR = 0.88). Among the six children who died (five DA, one FA), all experienced prior relapse or progression within 18 months. Conclusion Events in children with DA/FA in the setting of BWT occurred early. Caution should be taken about interpreting the impact of margin status outcomes in the context of contemporary multimodal therapy. Future targeted investigations in children with BWT and DA/FA are needed.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (10)
Daniel Benedetti
Vanderbilt University Medical Center
Conrad Fernandez
Professor Division of Pediatric Hematology Oncology
Dalhousie University
Daniela Perotti
Fondazione IRCCS Istituto Nazionale dei Tumori
Kara Maxwell
Assistant Professor
University of Pennsylvania
Alessandro Gasparetto
Assistant professor
Hospital for Sick Children
Brenda Gallie
Head Retinoblastoma Program
Hospital for Sick Children
Sarah Scollon
Assistant Professsor/Genetic Counselor
Baylor College of Medicine
Peter F. Ehrlich
-
Jonathan Finlay
Emeritus Professor
The Ohio State University College of Medicine
Jennifer Aldrink
Professor of Clinical Surgery and Pediatrics
Nationwide Children's Hospital
Make your next move.
Prepare your application
Review drafts before you send them.